Understanding AOD-9604
AOD-9604 is a fragment of the growth hormone molecule, isolated for the portion associated with fat metabolism. It is often described online in terms the evidence does not support — so here is the measured version.
Educational information only — not medical advice, diagnosis or treatment. Prescription peptides require clinical evaluation.
What is AOD-9604?
AOD-9604 corresponds to amino acids 176 to 191 of human growth hormone — the tail end of the molecule linked in laboratory work to fat metabolism, separated from the regions responsible for growth and glucose effects.
The intent behind that separation is specificity: the fragment was developed to explore the lipolytic side of growth hormone signalling without the tissue-growth or blood-sugar consequences of the full molecule.
It is important to be direct — human trials of AOD-9604 for obesity did not demonstrate meaningful weight loss versus placebo. It is discussed here because people search for it, and they deserve the accurate answer.
What makes it different
How AOD-9604 is thought to work
Step by step, in plain language — without overstating what has been demonstrated in people.
The lipolytic fragment
The C-terminal region of growth hormone is where fat-metabolism activity was localized in laboratory studies.
Fat-cell signalling
Preclinical work describes stimulation of lipolysis and reduced lipogenesis in adipose tissue.
No growth signalling
The fragment does not carry the growth-promoting region, and does not measurably raise IGF-1.
Glucose-neutral in studies
Unlike full growth hormone, it has not shown the insulin-resistance effect in the studies conducted.
The translation gap
Promising cell and animal data did not reproduce as clinically meaningful weight loss in human trials — the central fact about this molecule.
Potential benefits — and honest limits
These are areas of research interest, not promised outcomes. Individual response varies and depends heavily on what else is going on in your body.
Targeted mechanism
Isolates the fat-metabolism region of growth hormone from its growth-promoting regions.
No IGF-1 elevation
It does not appear to drive the growth signalling associated with the full hormone.
Glucose neutrality
Studies have not shown the blood-sugar impact associated with exogenous growth hormone.
Adjunct positioning
Where it is used at all, it is an adjunct within a metabolic plan — never the plan itself.
The honest caveat
Human obesity trials did not show significant weight loss versus placebo. Anyone promising otherwise is selling, not informing.
Better-evidenced options exist
For meaningful weight change, GLP-1 therapy has a far stronger evidence base and is the appropriate conversation to have first.
Who explores AOD-9604
These are the goals and concerns people are usually working on when AOD-9604 comes up in consultation. Fit is a clinical decision, not a checklist.
- People researching peptide options for body composition who want an evidence-based comparison
- Adults already working with nutrition, training and sleep who are evaluating adjunct options
- Anyone weighing peptide approaches against medically supervised GLP-1 therapy
When it isn't appropriate
What the evidence currently supports
Peptide research is genuinely early in most cases. We summarize it as it stands, gaps included — because you cannot make a good decision from marketing copy.
Positive preclinical work
Human trials disappointed
Regulatory status
Want the wider picture first? Read what peptide therapy is, browse the free guides and trackers, or keep reading on the blog.
Questions about AOD-9604
How Hormone Bliss approaches peptide therapy
Education first
You should understand what a molecule does — and what the evidence actually shows — before anyone prescribes it. That is why these pages exist and why they include the caveats.
Clinical review, always
Every request is reviewed by a licensed clinician against your history, medications and labs before anything is prescribed or shipped.
Individualized protocols
Dose, route and duration are chosen for you. We do not sell fixed stacks and we do not run protocols indefinitely.
Hormones come first
Peptides are rarely the missing piece on their own. If estrogen, progesterone, testosterone or thyroid are off, that is addressed first.
Coaching alongside
Sleep, protein, strength and stress determine most of your result. Coaching is part of the program, not an upsell.
Honest limits
If the evidence is thin, we say so. If a peptide is a poor fit for your goal, we will tell you that instead of selling it to you.
Where this can lead
Peptide Therapy
The program itself: physician review, an individualized protocol and coaching alongside it — not a vial in the mail.
Explore Peptide TherapyWhere this can lead
GLP-1 Weight Loss
Medically supervised GLP-1 therapy when the obstacle is primarily metabolic rather than hormonal.
Explore GLP-1 OptionsWhere this can lead
Bliss Membership
Doctor-formulated bioidentical hormone therapy with lab testing and ongoing guidance — usually the first thing to get right.
See If I QualifyReady to look at options? Browse the peptide menu and protocol builder, or book a complimentary consultation and talk it through first.
Find My Peptide MatchFind the peptide protocol that fits your goals
A short, structured match based on what you're actually trying to solve — then a licensed clinician reviews the whole picture before anything is prescribed.